Biogen Inc. is providing the company’s controversial and expensive new Alzheimer’s drug free of charge for some patients amid slow claim reviews by Medicare, according to sources familiar with the situation, including a doctor treating patients with the drug.

For both patients and their healthcare providers (HCPs), the requirement that prior authorizations (PAs) be obtained from health insurers for many branded and specialty medications continues to act as a significant roadblock, according to David Fidler, senior director product innovation at ConnectiveRx.

FCB Health Network president & CEO Dana Maiman announced Jill Lesiak joined Mosaic Group – the Network’s full-service payer and market access healthcare agency – as executive creative director.

Prevea Health and DocASAP will discuss how to create an access optimization strategy to drive measurable results for health systems and physician groups across the U.S.